The use of topical ocular hypotensive medication in eyes with OAG results in an increase in CT. This increase is relatively greater with bimatoprost 0.03% therapy compared to BTFC.
Purpose. To assess the repeatability and reproducibility of ocular biometry and intraocular lens (IOL) power measurements obtained by ophthalmology residents using an AL-Scan device, a novel optical biometer. Methods. Two ophthalmology residents were instructed regarding the AL-Scan device. Both performed ocular biometry and IOL power measurements using AL-Scan, three times on each of 128 eyes, independently of one another. Corneal keratometry readings, horizontal iris width, central corneal thickness, anterior chamber depth, pupil size, and axial length values measured by both residents were recorded together with IOL power values calculated on the basis of four different IOL calculation formulas (SRK/T, Holladay, and HofferQ). Repeatability and reproducibility of the measurements obtained were analyzed using the intraclass correlation coefficient (ICC). Results. Repeatability (ICC, 0.872-0.999 for resident 1 versus 0.905-0.999 for resident 2) and reproducibility (ICC, 0.916-0.999) were high for all biometric measurements. Repeatability (ICC, 0.981-0.983 for resident 1 versus 0.995-0.996 for resident 2) and reproducibility were also high for all IOL power measurements (ICC, 0.996 for all). Conclusions. The AL-Scan device exhibits good repeatability and reproducibility in all biometric measurements and IOL power calculations, independent of the operator concerned.
BackgroundPatients with ankylosing spondylitis (AS) have higher choroidal thickness values (CT) compared to controls.ObjectivesTo quantitatively asses the profile of CT in patients with AS using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients were reversible by infliximab therapyMethodsThirty-one patients with AS receiving infliximab therapy and 24 healthy controls were enrolled. Patient's clinical and demographic characteristics were recorded. Using OCT, we performed retinal imaging and choroidal thickness measurements in AS patients before and after 6 months of infliximab therapy, and in healthy controls who returned 6 months after the first visit. We compared patients before versus 6 months after infliximab therapy, as well as controls.ResultsPatients with AS had higher CT (mean± SD; 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm) (p=0.283), although this did not reach statistical significance. At 6 months after the first measurement, the mean CT was significantly decreased (after treatment with infliximab: 326.5±99.7μm vs. before: 347.5±114.4 μm, n=31, p=0.018) in AS group, but not in the control group (p=0.102). Retinal nerve fiber layer was significantly decreased at 6 months after treatment with infliximab in AS group (106.4±13.5 μm vs 105.0±13.0μm p=0.008).ConclusionsThis is the first study to evaluate the posterior eye segment in patients with AS using OCT. Our data indicate that CT abnormalities in active AS is reversible by therapy, and this CT decreasing effect of infliximab may be involved in its effective suppressing action of uveitis attacks in AS.ReferencesBalaskas K, Ballabeni P, Guex-Crosier Y. Retinal thickening in HLA-B27-associated acute anterior uveitis: evolution with time and association with severity of inflammatory activity. Invest Ophthalmol Vis Sci. 2012 14;53(10):6171–7.Kola M, Kalkışım A, Karkucak M, Turk A, Capkın E, Can I, Serdar OF, Mollamehmetoglu S, Ayar A. Evaluating of choroid thickness in Ankylosing spondylitis using optical coherence tomography. Ocular immunology and inflammation. 2014, 22(6):434–8.Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.